PARADIGM - En Bloc Trial With the EndoQuest Endoluminal Surgical (ELS) System
NCT ID: NCT06133387
Last Updated: 2026-01-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
56 participants
INTERVENTIONAL
2025-05-13
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The safety and effectiveness outcomes will be assessed intraoperatively and postoperatively at discharge and Days 7 and 30.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Transanal Resection of Rectal Lesions With the ColubrisMX ELS System
NCT04651764
Outcomes of Perforation After Colorectal Endoscopic Submucosal Dissection
NCT05728710
Prospective Cohort Study on the Safety and Efficacy of Endorobotics for Endoscopic Submucosal Dissection (Endorobotics ESD)
NCT06726798
Endoscopic Submucosal Dissection for Gastrointestinal Neoplasms
NCT01378507
Post-Market Clinical Follow-Up to Access & Visualize the Anus, Rectum, & Distal Colon During Transanal Procedures
NCT03323060
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The safety and effectiveness outcomes will be assessed intraoperatively and postoperatively at discharge, Day 7 (-2 +7 days) and Day 30 (-7 +14 days).
Subjects with lesions resected using the study device will be allocated into two different study arms:
Arm 1:
* Subjects with benign final pathology and R0 resection is achieved; or,
* Subjects with benign (but not pre-cancerous) final pathology without R0 resection.
Arm 2:
* Subjects with final pathology that is upstaged to cancer; or,
* Subjects with benign (and pre-cancerous) final pathology without R0 resection.
Subjects in Arm 1 will complete the study after Day 30. Arm 1 subjects in which R0 resection was not achieved should receive routine care, including any additional treatment as needed at the discretion of the physician, even if occurring after study exit at Day 30. Any non-study-related care of Arm 1 subjects occurring after study exit may be performed by the Investigator or transferred to another physician at the discretion of the Investigator and will not be collected for this trial.
Subjects in Arm 2 will undergo 5-year follow-up to assess long-term oncological outcomes including local recurrence, disease-free survival and overall survival.
To ensure a total of 50 subjects are included in the final analysis, the study may enroll up to 56 subjects at up to 5 clinical sites in the U.S. No individual site will be permitted to enroll more than 60% of the subjects in the final data set to ensure that a single site does not dominate the results and analysis. Enrollment will end when 50 subjects have completed 30-day follow-up or the maximum enrollment number has been reached, whichever occurs first.
In addition to the total number of enrolled subjects, each Investigator will enroll up to 2 lead-in cases. Lead-in cases will be analyzed separately in the final clinical study report.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
* Subjects with benign final pathology and R0 resection is achieved; or,
* Subjects with benign (but not pre-cancerous) final pathology without R0 resection.
Subjects in Arm 1 will complete the study after Day 30.
Endoscopic submucosal dissection using the ELS System
All subjects will undergo endoscopic submucosal dissection, with or without closure at the discretion of the Investigator, of benign lesions in the rectum and sigmoid colon.
Arm 2
* Subjects with final pathology that is upstaged to cancer; or,
* Subjects with benign (and pre-cancerous) final pathology without R0 resection.
Subjects in Arm 2 will undergo 5-year follow-up to assess long-term oncological outcomes including local recurrence, disease-free survival and overall survival.
Endoscopic submucosal dissection using the ELS System
All subjects will undergo endoscopic submucosal dissection, with or without closure at the discretion of the Investigator, of benign lesions in the rectum and sigmoid colon.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Endoscopic submucosal dissection using the ELS System
All subjects will undergo endoscopic submucosal dissection, with or without closure at the discretion of the Investigator, of benign lesions in the rectum and sigmoid colon.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subject has a BMI ≤ 50 kg/m2.
3. Subject has an ASA score of ≤ 3.
4. Subject has benign lesion(s) of the rectum or sigmoid colon, such as adenoma (with low- or high-grade dysplasia), neuroendocrine tumor, or other type of polyp as assessed by the most recent colonoscopy/flexible sigmoidoscopy.
5. Subject has lesion ≤ 7 cm in size (dimension of greatest extent) and ≤ 75% of the colorectal circumference as assessed by the most recent colonoscopy/flexible sigmoidoscopy.
6. Subject is eligible for standard endoscopic submucosal dissection.
7. Subject agrees to participate in the study by giving signed informed consent.
Exclusion Criteria
2. Subject has a history of inflammatory bowel disease.
3. Subject has an untreated active infection at the time of the procedure.
4. Subject is considered part of a vulnerable population (e.g., prisoners, mentally disabled).
5. Subject has a severe concomitant illness that drastically shortens life expectancy or increases risk of therapeutic interventions (e.g., cancer).
6. Subject is breastfeeding or pregnant or intends to become pregnant during the study.
7. Subject is currently enrolled in or discontinued within the last 30 days from a clinical trial of an investigational drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
8. Subject with EF ≤ 45, high cardiac or high pulmonary risk (these subjects require clearance from a cardiologist and pulmonologist, as applicable).
9. Subject on preoperative blood thinners, such as coumadin or heparin, that cannot be weaned prior to surgery.
10. Subject is moderately or severely immunocompromised.
11. In the opinion of the Investigator, the subject is unable to comply with the requirements of the study protocol or is unsuitable for the study for any reason.
1. Inadequate bowel prep.
2. Complex anatomical findings not feasible for an endoluminal approach.
3. Anatomical narrowing distal to the lesion site.
4. Lesion not located in the rectum or sigmoid colon.
5. Lesion size \>7 cm (dimension of greatest extent) or occupies \>75% of the colorectal circumference.
6. Lesion demonstrates characteristics indicative of invasive carcinoma, such as failure to lift upon submucosal injection, or any other features that raise the Investigator's suspicion of cancer.
7. In the opinion of the Investigator, the subject and/or subject anatomy is not suitable for study device use for any reason.
8. Lesion location not accessible by the study device.
22 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
EndoQuest Robotics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic
Scottsdale, Arizona, United States
AdventHealth
Orlando, Florida, United States
Brigham and Women's Hospital
Boston, Massachusetts, United States
Cleveland Clinic
Cleveland, Ohio, United States
HCA Healthcare
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CIP-0001-Rev E
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.